Vascular AgingNCT07591337
SNRK & Vascular Endothelial Aging
An observational study of Vascular Aging, run by Tianjin Medical University at 1 site in China.
Trial summary
Cardiovascular diseases pose a serious threat to public health, and their prevalence is on the rise year by year. Vascular aging is an independent risk factor for cardiovascular diseases, and endothelial cell senescence is an early event in vascular aging. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Vascular Aging
- What is being tested?
- serum tests and carotid ultrasound test
- How many people
- 180 participants
- Where
- 1 siteChina
- Study dates
- 1 May 2026to 30 Apr 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Estimated by statistical analysis, a total of 180 subjects were included from individuals who come for physical examinations or medical visits to the leading and collaborating administrations of this project, and meet the inclusion criteria between April 2026 and March 2029.
Who may be able to join
- Aged 18-80 years, with the capacity to make decisions independently or represented by an authorized legal guardian;
- Able to provide complete personal information, medical history, and lifestyle history (e.g., smoking and alcohol consumption history);
- No history of severe cardiovascular disease, and deemed eligible for inclusion by a physician.
Who cannot join
- Women who are pregnant or may become pregnant;
- Patients with a history of neurological disorders, tumors, severe cardiovascular or pulmonary disease, liver failure, kidney failure, or blood disorders;
- Patients who have undergone carotid stenting, carotid endarterectomy, or other similar procedures, or who have unilateral carotid artery occlusion due to any cause;
- Patients who have participated in another clinical trial within the past 4 weeks;
- Individuals deemed unsuitable for this clinical trial by the investigators.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052
Xintong Ge, M.D., xge@tmu.edu.cn
About this study
Official title: The Association Between SNRK and Vascular Endothelial Aging
Cardiovascular diseases pose a serious threat to public health, and their prevalence is on the rise year by year. Vascular aging is an independent risk factor for cardiovascular diseases, and endothelial cell senescence is an early event in vascular aging. Its occurrence can lead to endothelium-dependent vasodilation dysfunction, reduced vascular permeability, and the release of the senescence-associated secretory phenotype (SASP). These vascular pathological changes further damage the vascular media, leading to vascular remodeling and reduced compliance, accelerating the progression of atherosclerosis, and ultimately resulting in cardiovascular diseases such as coronary heart disease and hypertension. Recent research of the investigators has revealed that SNRK, a new member of the AMPK family of cellular energy sensors, plays a key regulatory role in vascular development. Based on this finding, the investigators propose the scientific hypothesis that SNRK responds to both physiological and pathological aging stimuli through differential mechanisms and regulates the process of endothelial cell senescence. In this study, the investigators will explore the correlation between SNRKAS and carotid vascular structure and endothelial function by measuring the levels of the SNRK upstream lncRNA (SNRKAS) in participants' peripheral blood, in conjunction with carotid ultrasound examinations. The findings will provide a solid scientific basis for elucidating new mechanisms underlying the onset and progression of vascular aging and for identifying novel therapeutic targets.
- Conditions
- Vascular Aging
- Being tested
- serum tests and carotid ultrasound test
- Keywords
- SNRK, carotid atherosclerosis, vascular endothelial cells, cell senescence, vascular aging
- Medical subject headings
- Carotid Artery Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
serum tests and carotid ultrasound testDiagnostic test
- 10 mL of venous blood was drawn from each participant to measure blood lipids and serum levels of SNRKAS (using RT-qPCR), and to perform transcriptomic analysis.
- Carotid ultrasound was used to measure circumferential strain and pulse wave velocity in both carotid arteries to assess the degree of arterial stiffness.
| Study group | Role | What they receive |
|---|---|---|
| < 40 years old | Participants of < 40 years old. Receives: Diagnostic Test: serum tests and carotid ultrasound test | |
| 40-60 years old | Participants of 40-60 years old. Receives: Diagnostic Test: serum tests and carotid ultrasound test | |
| > 60 years old | Participants of > 60 years old. Receives: Diagnostic Test: serum tests and carotid ultrasound test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum levels of SNRKAS detected by RT-PCR
serum levels of SNRKAS (fold change)
Measured: At enrollment
Degree of bilateral carotid artery stenosis detected by Doppler ultrasound
Intima-media thickness (mm) and lumen diameter (mm) of bilateral common carotid artery and internal carotid artery
Measured: At enrollment
Pulse wave velocity in both carotid arteries detected by Doppler ultrasound
Peak systolic velocity (cm/s) of bilateral common carotid artery and internal carotid artery
Measured: At enrollment
Secondary outcomes (1)
Blood lipids levels detected by automated biochemical analyzer (LABOSPECT 008, Hitachi)
Total Cholesterol (mmol/L), Triglycerides (mmol/L), High-Density Lipoprotein (mmol/L), Low-Density Lipoprotein (mmol/L)
Measured: At enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2026
- Study start1 May 2026
- Primary completion30 Apr 2029 (estimated)
- Study completion30 Apr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vascular AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tianjin Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xintong Ge, Tianjin Medical University
- Investigators
- Minghui Zou, Ph.D., Study chair, mhzou@tmu.edu.cn
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07591337
- Sponsor's protocol ID
- IRB2026-YX-172-01
- Status last verified
- May 2026
- First submitted
- 6 May 2026
- Last updated
- 15 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Association Between SNRK and Vascular Endothelial Aging
- ClinicalTrials.gov ID
- NCT07591337
- Acronym / sponsor ID
- IRB2026-YX-172-01
- Conditions
- Vascular Aging
- Keywords
- SNRK, carotid atherosclerosis, vascular endothelial cells, cell senescence, vascular aging
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- Tianjin Medical UniversityUniversity, hospital or other
- Study start
- 1 May 2026 (actual)
- Primary completion
- 30 Apr 2029 (estimated)
- Study completion
- 30 Apr 2029 (estimated)
- First posted
- 15 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiovascular diseases pose a serious threat to public health, and their prevalence is on the rise year by year. Vascular aging is an independent risk factor for cardiovascular diseases, and endothelial cell senescence is an early event in vascular aging. Its occurrence can lead to endothelium-dependent vasodilation dysfunction, reduced vascular permeability, and the release of the senescence-associated secretory phenotype (SASP). These vascular pathological changes further damage the vascular media, leading to vascular remodeling and reduced compliance, accelerating the progression of atherosclerosis, and ultimately resulting in cardiovascular diseases such as coronary heart disease and hypertension. Recent research of the investigators has revealed that SNRK, a new member of the AMPK family of cellular energy sensors, plays a key regulatory role in vascular development. Based on this finding, the investigators propose the scientific hypothesis that SNRK responds to both physiological and pathological aging stimuli through differential mechanisms and regulates the process of endothelial cell senescence. In this study, the investigators will explore the correlation between SNRKAS and carotid vascular structure and endothelial function by measuring the levels of the SNRK upstream lncRNA (SNRKAS) in participants' peripheral blood, in conjunction with carotid ultrasound examinations. The findings will provide a solid scientific basis for elucidating new mechanisms underlying the onset and progression of vascular aging and for identifying novel therapeutic targets.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| < 40 years old | – | Diagnostic Test: serum tests and carotid ultrasound testParticipants of < 40 years old. |
| 40-60 years old | – | Diagnostic Test: serum tests and carotid ultrasound testParticipants of 40-60 years old. |
| > 60 years old | – | Diagnostic Test: serum tests and carotid ultrasound testParticipants of > 60 years old. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Estimated by statistical analysis, a total of 180 subjects were included from individuals who come for physical examinations or medical visits to the leading and collaborating administrations of this project, and meet the inclusion criteria between April 2026 and March 2029.
Key inclusion criteria (3 listed)
- Aged 18-80 years, with the capacity to make decisions independently or represented by an authorized legal guardian;
- Able to provide complete personal information, medical history, and lifestyle history (e.g., smoking and alcohol consumption history);
- No history of severe cardiovascular disease, and deemed eligible for inclusion by a physician.
Key exclusion criteria (5 listed)
- Women who are pregnant or may become pregnant;
- Patients with a history of neurological disorders, tumors, severe cardiovascular or pulmonary disease, liver failure, kidney failure, or blood disorders;
- Patients who have undergone carotid stenting, carotid endarterectomy, or other similar procedures, or who have unilateral carotid artery occlusion due to any cause;
- Patients who have participated in another clinical trial within the past 4 weeks;
- Individuals deemed unsuitable for this clinical trial by the investigators.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| serum tests and carotid ultrasound test1. 10 mL of venous blood was drawn from each participant to measure blood lipids and serum levels of SNRKAS (using RT-qPCR), and to perform transcriptomic analysis. 2. Carotid ultrasound was used to measure circumferential strain and pulse wave velocity in both carotid arteries to assess the degree of arterial stiffness. | Diagnostic test | 40-60 years old, < 40 years old, > 60 years old |
Primary outcome
Serum levels of SNRKAS detected by RT-PCR
Time frame: At enrollment
serum levels of SNRKAS (fold change)
Degree of bilateral carotid artery stenosis detected by Doppler ultrasound
Time frame: At enrollment
Intima-media thickness (mm) and lumen diameter (mm) of bilateral common carotid artery and internal carotid artery
Pulse wave velocity in both carotid arteries detected by Doppler ultrasound
Time frame: At enrollment
Peak systolic velocity (cm/s) of bilateral common carotid artery and internal carotid artery
1 secondary outcome
Blood lipids levels detected by automated biochemical analyzer (LABOSPECT 008, Hitachi)
Time frame: At enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
- Individual participant dataSharing planned: Yes
Related trials for Vascular Aging
Active, not recruitingObservational study
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
Diabetes, Cerebrovascular Disease
Not yet recruitingPhase 2
Fisetin for Improving Vascular Function in Older Adults: A Phase II Clinical Trial
Aging, Endothelial Dysfunction
Not yet recruiting
High-Velocity Resistance Training for Brain Blood Flow and Cognitive Function in Older Adults
At Risk for AD-dementia, With Subjective Cognitive Decline, At Risk for Cognitive Decline
Recruiting
NightWare and Cardiovascular Health in Veterans With PTSD
Post-traumatic Stress Disorder (PTSD), Cardiovascular Diseases
Recruiting
Virtual Reality and Field Training to Enhance Community Walking After Stroke
Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Minghui Zou, Ph.D. study chair
mhzou@tmu.edu.cn
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Vascular Aging, run by Tianjin Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xintong Ge, M.D. (86-022-60362237, xge@tmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum levels of SNRKAS detected by RT-PCR (time frame: At enrollment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.